Clinical trial finds novel therapy markedly reduced lipoproteina levels in people with CVD

#Clinicaltrial #cardiovascula #noveltherapy #lipoproteina
Lipoprotein(a) is a special type of bad cholesterol that is believed to contribute to heart disease, but there are no approved pharmacological therapies to decrease its concentration in the bloodstream. Olpasiran is an investigational drug that reduces lipoprotein(a) concentration by degrading the RNA that codes for a protein that is an essential part of the molecule.

Researchers at Brigham and Women’s Hospital conducted a phase 2, randomized, placebo-controlled clinical trial of olpasiran in patients with established cardiovascular disease to evaluate its safety and tolerability and to identify an optimal dose of olpasiran for reducing lipoprotein(a) levels.

Get the latest medical and health news at medicaldialogues.in
Follow us on
Twitter:   / medicaldialogs  
Facebook:   / medicaldialogues  
Instagram:   / medicaldialogues  
LinkedIn:   / medical-dialogues  
Website: https://medicaldialogues.in/